MX2023001865A - Composiciones de forma de dosificación que comprenden un inhibidor de btk y mutantes de este. - Google Patents

Composiciones de forma de dosificación que comprenden un inhibidor de btk y mutantes de este.

Info

Publication number
MX2023001865A
MX2023001865A MX2023001865A MX2023001865A MX2023001865A MX 2023001865 A MX2023001865 A MX 2023001865A MX 2023001865 A MX2023001865 A MX 2023001865A MX 2023001865 A MX2023001865 A MX 2023001865A MX 2023001865 A MX2023001865 A MX 2023001865A
Authority
MX
Mexico
Prior art keywords
inhibitor
btk
mutants
dosage form
form compositions
Prior art date
Application number
MX2023001865A
Other languages
English (en)
Inventor
Yi Chen
Original Assignee
Guangzhou Lupeng Pharmaceutical Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/047196 external-priority patent/WO2021066958A1/en
Application filed by Guangzhou Lupeng Pharmaceutical Company Ltd filed Critical Guangzhou Lupeng Pharmaceutical Company Ltd
Publication of MX2023001865A publication Critical patent/MX2023001865A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente descripción se proporcionan composiciones de comprimido farmacéuticas que comprenden un ácido orgánico (tal como ácido fumárico) y un compuesto de Fórmula (I), o un N-óxido de este, solvato, polimorfo, tautómero, estereoisómero, una forma isotópica o un profármaco de dicho compuesto de Fórmula (I) o N-óxido de este: (VER FORMULA) en donde el compuesto de Fórmula (I) es un inhibidor de la tirosina quinasa de Bruton.
MX2023001865A 2020-08-14 2021-08-13 Composiciones de forma de dosificación que comprenden un inhibidor de btk y mutantes de este. MX2023001865A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063066105P 2020-08-14 2020-08-14
PCT/US2020/047196 WO2021066958A1 (en) 2019-10-05 2020-08-20 Inhibitor of btk and mutants thereof
PCT/US2021/045867 WO2022036171A1 (en) 2020-08-14 2021-08-13 Dosage form compositions comprising an inhibitor of btk and mutants thereof

Publications (1)

Publication Number Publication Date
MX2023001865A true MX2023001865A (es) 2023-05-09

Family

ID=80248192

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001865A MX2023001865A (es) 2020-08-14 2021-08-13 Composiciones de forma de dosificación que comprenden un inhibidor de btk y mutantes de este.

Country Status (10)

Country Link
US (1) US20230346779A1 (es)
EP (1) EP4196124A1 (es)
JP (1) JP2023537626A (es)
KR (1) KR20230051200A (es)
CN (1) CN116406259A (es)
AU (1) AU2021326530A1 (es)
CA (1) CA3189235A1 (es)
IL (1) IL300428A (es)
MX (1) MX2023001865A (es)
WO (1) WO2022036171A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109053523B (zh) 2005-10-07 2022-03-25 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek抑制剂的吖丁啶
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
US11100492B2 (en) 2018-02-19 2021-08-24 Peter Garrett General purpose re-loadable card aggregation implementation
CN113939292A (zh) * 2019-02-25 2022-01-14 广州麓鹏制药有限公司 Btk及其突变体的抑制剂
WO2021066958A1 (en) * 2019-10-05 2021-04-08 Newave Pharmaceutical Inc. Inhibitor of btk and mutants thereof

Also Published As

Publication number Publication date
IL300428A (en) 2023-04-01
EP4196124A1 (en) 2023-06-21
US20230346779A1 (en) 2023-11-02
CA3189235A1 (en) 2022-02-17
JP2023537626A (ja) 2023-09-04
AU2021326530A8 (en) 2023-04-27
KR20230051200A (ko) 2023-04-17
CN116406259A (zh) 2023-07-07
WO2022036171A1 (en) 2022-02-17
AU2021326530A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
PH12018502227A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
PH12021550995A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
US20090039811A1 (en) Inhibitors of HSP90
BR0209431A (pt) Novos compostos de 4-anilinoquinolino-3-carboxamidas
SE0400284D0 (sv) Novel compounds
WO2008076779A2 (en) 2-(piperidin-4-yl0xy)pyrimidin-4-amine derivatives as deoxycytidine kinase inhibitors for the treatment of cancer
MX2022008881A (es) Compuesto heterociclico de pirimidin-4(3h)-ona, metodo de preparacion del mismo y su uso farmaceutico.
GB0112348D0 (en) Compounds
AU2020281332A8 (en) Dna-dependent protein kinase inhibitor
MX2022013054A (es) Derivados de imidazolidinona y uso medico de los mismos.
MX2021003662A (es) Derivado de aminonorbornano y metodo de fabricacion del mismo y uso del mismo.
MX2019006843A (es) Inhibidor de cdk4/6.
MX2023005086A (es) Compuestos de pirimidina, composiciones y aplicaciones medicas de esta.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
WO2021012049A8 (en) Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors
MX2021003739A (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2021013576A (es) Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo.
MX2023011829A (es) Derivados de uracilo como inhibidores de trpa1.
WO2018031707A1 (en) Acyl benzo[d]thiazol-2-amine and their methods of use
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
MX2023001865A (es) Composiciones de forma de dosificación que comprenden un inhibidor de btk y mutantes de este.
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.